Royalty Pharma plc Class A (RPRX)
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RPRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $32.80B
- P/E (TTM)
- 30.19
- Forward P/E
- 9.90
- EPS (TTM)
- $1.88
- Dividend yield
- 1.60% ($0.91)
- Ex-dividend date
- Aug 14, 2026
- 52-week range
- 35.23 – 64.38
- Day range
- 56.41 – 57.16
- Volume / Avg
- 3.67M / 2.92M
- Beta
- —
- Shares outstanding
- 445.28M
- Next earnings
- Nov 4, 2026
52-week range
RPRX stock today
On Oct 7, RPRX ended the session at $56.76, adding $0.32 (0.57%), versus the S&P 500's 0.22% decline. At this level, RPRX sits in the middle of its 52-week range of $35.23 to $64.38: 11.8% below the high, set on Sep 4, 2026 and 61.1% above the low. RPRX is up 46.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 57.2%.
At 30.2x trailing earnings, Royalty Pharma trades in line with the peer-group median of 28.9x. Its forward P/E of 9.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Royalty Pharma's next earnings report is expected on Nov 4, 2026. Royalty Pharma pays an annual dividend of $0.91 per share, a 1.60% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Royalty Pharma
Company profileRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pablo Legorreta
- Headquarters
- New York, NY
- Employees
- 100
- IPO year
- 2020
- Website
- royaltypharma.com
Financial highlights
Full financialsIn fiscal 2025, Royalty Pharma generated $2.38 billion in revenue, up 5.1% from fiscal 2024. Net income was $770.9 million (-10.2% year over year), for a net margin of 32.4% versus a median of 37.9% in the prior 5 years. Operating margin was 65.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Growth | +5.06% | -3.86% | +5.24% | -2.28% | +7.87% |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M |
| EPS (diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$65.38+15.19%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $1.18
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.04 vs —
Dividends
Dividend history- Annual dividend
- $0.91
- Dividend yield
- 1.60%
- Last payment
- $0.235
- Ex-dividend date
- Aug 14, 2026
RPRX news
All RPRX newsRoyalty Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs RPRX |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs RPRX |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs RPRX |
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs RPRX |
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs RPRX |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs RPRX |
| INSMInsmed Incorporated | 101.74 | -3.32% | $22.22B | vs RPRX |
| VTRSViatris Inc. | 17.49 | -0.29% | $20.09B | vs RPRX |
Indexes, lists and sector
Appears in lists
Royalty Pharma stock FAQ
What is Royalty Pharma's stock price today?
RPRX last traded at $56.76 as of Oct 7, 4:00 PM EDT, up 0.57% on the day. Prices are delayed at least 15 minutes.
Does Royalty Pharma pay a dividend?
Yes. Royalty Pharma pays $0.91 per share annually, a 1.60% yield. The most recent dividend of $0.235 had an ex-dividend date of Aug 14, 2026.
When is Royalty Pharma's next earnings date?
Royalty Pharma is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $1.18.
What is RPRX's P/E ratio?
RPRX trades at a trailing P/E ratio of 30.19 and a forward P/E of 9.90, compared with a median of 28.9 for its closest peers.
Who is Royalty Pharma's CEO?
Mr. Pablo Legorreta is the chief executive officer of Royalty Pharma plc Class A, which has about 100 employees.
What is the RPRX 52-week high?
The 52-week high for RPRX is $64.38 and the 52-week low is $35.23. The stock is currently 11.8% below its high.